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Abstract  
Background: Life-long ART for pregnant and breastfeeding women (Option B+) was rolled-
out in Zimbabwe from 2014 with simultaneous raising of the CD4 treatment-threshold in non-
pregnant/breastfeeding adults and children >5 years to 500 cells/mm3.  
Methods: Lablite is an implementation project in Zimbabwe, Malawi and Uganda evaluating 
ART rollout. Routine patient-level data were collected for 6 months prior to and 12 months 
after Option B+ rollout at a district hospital and three primary care facilities in Zimbabwe (two 
with outreach ART; one with no ART provision prior to Option B+).   
Results: Between September 2013-February 2015 there were 1,686 ART initiations in the 
four facilities; 91% adults and 9% children aged <15 years. In the three facilities with 
established ART, initiations rose from 300 during 6 months before Option B+ to 869 (2.9-
fold) and 463 (1.5-fold) respectively 0-6 months and 6-12 months after Option B+. Post 
Option B+, an estimated 43% of pregnant/breastfeeding women needed ART for their own 
health, based on WHO stage 3/4 or CD4≤350 (64% for CD4≤500).  74 (22%) men and 123 
(34%) non-pregnant/breastfeeding women initiated ART with CD4>350 after the CD4-
threshold increase. Estimated 12-month retention on ART was 79% (69%-87%) in Option B+ 
women (significantly lower in younger women, p=0.01), versus 93% (91%-95%) in other 
adults (difference p<0.001).  
Conclusions: There were increased ART initiations in all patient groups following 
implementation of WHO 2013 guidelines. Retention of Option B+ women was poorer than 
retention of other adults; younger women require attention as they are more likely to 
disengage from care.   
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Introduction 
WHO 2013 guidelines promoted expanded eligibility for ART by raising the CD4 threshold for 
treatment initiation from 350 to 500 cells/mm3 for HIV-infected individuals aged 5 years and 
over; ART was recommended for all children below 5 years; Option B (ART during 
pregnancy and breastfeeding) or Option B+ (provision of ART for life for 
pregnant/breastfeeding women) for high fertility/high HIV prevalence countries was 
recommended over Option A (ART perinatally only) for PMTCT. 1 The PROMISE trial 
subsequently confirmed superiority of Option B over Option A for reducing MTCT. 2 Malawi 
was the first country to implement ‘Option B+’ in September 2011. 3 By 2015, most 
low/middle-income countries were piloting, rolling-out or implementing Option B+. 4 
Advantages of Option B+ over previous PMTCT Option A and Option B (ART during 
pregnancy and breastfeeding)  include: simplification of PMTCT program requirements 
(notably no requirement for a CD4 count result to be returned before ART initiation); 
extended protection from MTCT in future pregnancies from conception; prevention against 
sexual transmission to serodiscordant partners; benefit to the woman’s health of earlier 
treatment and avoiding the risks of stopping and starting ART; and a simple message to 
communities that once ART is started, it is taken for life. 5  
 
Striking increases in pregnant women accessing ART have been seen in countries 
implementing Option B+, although the first countries to implement Option B+ tended to have 
low PMTCT coverage. 6,7  Because Option B+ is relatively new, there are few reports of 
outcomes from National programmes. In the first National cohort of Option B+ women in 
Malawi retention at 12 months, when most African women are still breastfeeding, was only 
77%; 7 retention within more recent cohorts is similar, 8 emphasizing the need for support 
measures for this population. At Elizabeth Glazer Pediatric AIDS Foundation sites in Uganda 
early 6 month data suggests slightly higher retention. 6 
  
Zimbabwe adopted Option B+ after a National Stakeholder Consultation in 2013 9 and began 
piloting in July 2013 with roll-out in 2014. National guidelines issued at the end of 2013 also 
included recommendations to treat all HIV-infected children below 5 years and to treat older 
children and adults with WHO stage 1/2 disease and CD4 count <500. 10 Prior to the 
introduction of Option B+, the PMTCT program (providing Option A) in Zimbabwe was 
functioning comparatively well (78% ART coverage in pregnant women in 2013 11), 
population HIV and CD4 testing levels were high, and ART coverage was also high at 77% 
in treatment-eligible adults in 2013 12), although considerably lower in children at 46%. 12 
However, ART clients were frequently travelling long distances to access treatment and ART 
provision in primary care (where available) was principally through outreach teams visiting 
from local hospitals. Implementation of Option B+ necessitated integration of ART into all 
PMTCT settings where services are mostly delivered by nurses at the primary health facility 
level; for Zimbabwe this required expanding the ART program from 1006 to 1560 facilities 
between 2013 and 2015. 9 
 
The Lablite Project 13 worked with Ministries of Health in Malawi, Uganda and Zimbabwe to 
evaluate roll-out of ART at four non-research sites (each comprising a district hospital and 2-
4 linked rural primary care facilities). In Zimbabwe, Lablite was present in Zvimba, a rural 
district west of Harare, with 270,000 inhabitants and estimated HIV prevalence of 14%. The 
district includes 2 secondary-care facilities and 31 primary care facilities. Here we report on 
ART provision during the 6 months prior to implementation of Option B+ (March 2014) and 
for the following 12 months, in one of the district hospitals and three primary care facilities. 
The CD4 threshold for starting ART was raised from 350 to 500 cells/mm3  in January 2014, 
two months earlier than implementation of Option B+, but in practice few initiations at higher 
CD4s occurred before Option B+ was rolled-out. Aims of this paper were to describe the 
impact of Option B+ provision and the increase in CD4 initiation threshold on ART provision 
and to quantify retention on ART, identifying predictors of high retention in care. 
 
Methods 
The Lablite facilities were selected in consultation with Ministry of Health and Child Welfare 
(MOHCW). A “hub-spoke” approach was taken with Banket District Hospital being the hub 
for three primary care facilities; prior to the Lablite project two facilities (Nyabira, 
Mutorashanga) were benefiting from ART provision by Banket District Hospital outreach 
teams 2-weekly and one facility (Zowa) had no ART provision. In collaboration with 
MOHCW, healthcare workers were trained and mentored on site using national training 
materials, supplemented by a checklist for monitoring patients on ART and a handbook. 
Staff at Banket District Hospital were trained first and they mentored staff in the primary care 
facilities.  The primary care facilities then received accreditation as ART-initiating and follow-
up sites. 
 
Routine individual patient-level data were collected regularly from ART registers, 
appointment registers and facility patient cards for all patients newly registered on ART 
between September 2013 and February 2015 by a data capturer independent from clinic 
staff. Registrations include patients who are initiating ART and patients described as 
“transfers-in” who have started ART at another healthcare facility and are moving facility for 
follow-up on ART (during this study, often due to primary care facilities now providing full 
ART services, when they had not previously). Defaulters (no visit for 90 days) were cross-
checked with clinic defaulter lists (lists the nurses are required to keep within each clinic to 
identify defaulters for MOHCW reporting). Data were entered into bespoke database tools 
that mimicked the clinic paper-based tools.  
 
Reasons for starting ART were coded for analysis in a hierarchical manner as follows: 
children <15 years, adults with WHO stage 3/4 disease (including tuberculosis), pregnant 
post-Option B+, breastfeeding post-Option B+, CD4<threshold. Pregnancy and 
breastfeeding were coded as reasons for initiation above CD4 for two reasons: (1) Option B+ 
women started ART immediately without waiting for CD4 results; and (2) not all 
pregnant/breastfeeding women have CD4 results.  Current outcome at last data collection 
(between March and June 2015) was used to estimate retention on ART at end of follow-up, 
defined as 28 February 2015 (gaps in care prior to this were ignored). Patients who 
transferred-out to a new health facility were censored at the date of transfer. 
 
Comparisons of initiation characteristics were planned between 6-month time periods, pre 
Option B+ and 0-6 and 7-12 months post Option B+. Retention in care was estimated 
separately for new ART initiations and patients who transferred-in on ART. Comparisons of 
retention on ART were planned between facilities and for new ART initiations between 
Option B+ women and other adults. Proportions were compared using chi-square tests. 
Rank sum tests were used to compare distributions of continuous variables. Retention in 
care at 6 and 12 months was estimated by the Kaplan-Meier survivor function.  Hazard ratios 
(HRs) were estimated using Cox regression; HRs and p-values presented in the text to 
assess differences in retention by patient-level characteristics and facility are from 
univariable models (log rank tests gave similar p-values, data not shown). Multivariable Cox 
models were selected by backwards selection with significance level 0.1; continuous 
variables were included as fractional polynomials. In patients who started ART for WHO 3/4 
disease or CD4<threshold we fitted separate models for the risks of death and default 
including all the predictors identified for the combined endpoint (cause specific HRs are 
presented). Cumulative incidence of death and default were estimated using a competing 
risks framework.14 STATA version 13.1 was used. 
 
Role of the funding source 
The study was funded by DFID, UK who had no role in study design, collection, analysis and 
interpretation of data, the writing of the paper or the decision to submit for publication. The 
corresponding author had full access to all the data. 
 
Results 
Between September 2013 and February 2015 there were 2,088 ART registrations across the 
four facilities, including 1,686 (81%) new ART initiations and 402 (19%) patients already on 
ART who transferred in from an alternative health facility; 702 (42%) new initiations and 277 
(69%) transfers-in were at the primary care facilities.  
 
In the three facilities with established ART provision prior to Option B+ implementation, there 
were 300 ART initiations in the six months prior to Option B+ roll-out compared to 869 and 
463 initiations in the 0-6 months and 6-12 months afterwards respectively, corresponding to  
2.9- and 1.5-fold increases, with the largest in the first quarter (table 1, figure 1). Initiations in 
children <15 years comprised 36 (12%), 60 (7%) and 43 (9%) of ART initiations in the same 
three respective periods. Infants ≤2 years were in the minority and were seen primarily at the 
hospital; 37/92 (40%) children were ≤2 years at the hospital compared with 3/47 (6%) at 
primary care facilities (p<0.001). Throughout follow-up, adult males initiating ART were older 
(p<0.001) and had lower pre-ART CD4s than non-pregnant/breastfeeding females (p<0.001) 
(Table 1).  From March 2014, the median (IQR) pre-ART CD4 rose from 143 (71-243) to 216 
(104-326) in men (p<0.001) and from 192 (89-263) to 279 (161-396) in non-
pregnant/breastfeeding women (p<0.001). However, even between March 2014-February 
2015, 79/329 (24%) men and 47/362 (13%) non-pregnant/breastfeeding women had pre-
ART CD4≤100 cells/mm3. There were 3 ART initiations in men at the hospital where reason 
given for initiation was “male partner of an Option B+ female”; although all were WHO stage 
1, CD4s at initiation were 66, 313 and 470 cells/mm3 so they were eligible for treatment for 
their own health. 
 
Over the six months prior to rollout of Option B+, 34 (24%) women initiating ART were 
pregnant/breastfeeding, including 3 early Option B+ initiations at the hospital; excluding 
these 3 and one woman who was not WHO staged, 21/30 (70%) had WHO stage 3/4 
disease. In contrast, in the first quarter after Option B+ rollout, initiations rose to 269 among 
pregnant/breastfeeding women (corresponding to a 16-fold increase) and then reduced to 
82, 42 and 42 in the subsequent 3 quarters (a 6-fold increase over the first year after Option 
B+). After Option B+, 59/435 (13%) of pregnant/breastfeeding women were WHO stage 3 at 
ART initiation and none had stage 4 disease. CD4 data were incomplete (only 190/376 
(51%) with WHO stage 1/2 had a CD4 recorded); 64 (34%) stage 1/2 women had ≤350 
cells/mm3 and 47 (25%) had 351-500 cells/mm3, implying that overall, 43% of 
pregnant/breastfeeding women would have been eligible for treatment for their own health 
based on WHO 2010 disease progression criteria (WHO stage 3/4 or CD4≤350 cells/mm3) 
or 64% based on WHO 2013 criteria (WHO stage 3/4 or CD4≤500 cells/mm3). Median age at 
ART initiation in pregnant/breastfeeding women was similar pre- and post- Option B+ (table 
1); but the proportion of adolescents <20 years increased from 1 (3%) before Option B+ to 
25 (7%) in the first six months and 13 (15%) in the second six months post Option B+ (trend 
p=0.008). 
 
In Zowa, a primary care facility, where ART provision was started later and alongside Option 
B+ rollout (from April 2014), there were 54 ART initiations, including 6 in children <15 years 
(figure 1).  
 
Median follow-up in individuals newly initiating ART was 8 (3-11) months. Retention on ART 
in 1,140 adults who started ART for disease progression (all patients pre-Option B+ 
implementation; pregnant/breastfeeding women with WHO stage 3/4 disease and non-
pregnant/breastfeeding patients post Option B+ implementation) was 95% (95% CI 93%-
96%) at 6 months including 12 deaths and 39 losses to follow-up (LTFU); 12 month retention 
was 93% (91%-95%) (18 deaths, 40 LTFU). Figure 2a shows the cumulative incidence of 
death and default across all sites. Retention varied between sites (Table 2; p<0.001); 12 
month retention in the primary care facilities was 86% (80%-90%) compared with 98% (96%-
99%) at the hospital. There was no evidence that retention-in-care was worse when ART 
was initiated after Option B+ had rolled out compared with before Option B+ (Table 2). 
Retention was higher in patients with higher CD4 and lower in pregnant/breastfeeding 
patients (pre-Option B+ or also WHO 3/4 stage); when we looked at the risks of death and 
LTFU separately, the CD4-effect was predominantly due to an increased risk of death in 
patients with low CD4 whereas pregnancy/breastfeeding predicted higher LTFU but not 
higher mortality (table 3). Among WHO stage 1/2 patients, those with CD4>350 had similar 
retention to those with CD4≤350 (HR 1.11 (0.63-1.94)). 
 
Retention on ART in 386 women who newly started ART for Option B+ was 85% (81%-88%) 
at 6 months (1 death, 53 LTFU) and 79% (69%-87%) at 12 months (3 deaths, 55 LTFU); this 
was significantly lower than retention in the adults starting ART for WHO 3/4 or 
CD4<threshold (across all time periods: HR 3.09 (2.15-4.46); p<0.001; restricted to March 
2014 onwards: HR 4.00 (2.59-6.09); p<0.001). Retention differed markedly by age at 
initiation, being lower in younger women (Table 2, Figure 2b). Retention did not differ by pre-
ART CD4 (Table 2). Although 32 women were LTFU by one month, 20/32 attended one post 
ART initiation visit (median 14 days after starting ART). Importantly, in the subgroup of 
women who started ART during pregnancy/breastfeeding with WHO stage 3/4 or CD4≤350 
there was no evidence for worse retention after Option B+ implementation than before (HR 
0.78 (0.28-2.16)). 
 
Among 145 children <15 years at ART initiation there were 3 (2%) deaths, 16 (11%) LTFU 
and 10 (7%) transfers-out. The 3 children who died were all seen at the hospital; two 3 year 
olds died very soon after starting ART (13 days; 45 days) and one 2 year old died 12 months 
after initiation. At 6 months, retention on ART was 87% (80%-92%) and at 12 months it was 
85% (77%-91%). We found no evidence that retention at 12 months in the primary care 
facilities (94% (83%-98%)) was worse than at the hospital (79% (67%-88%)).  
 
Retention on ART in the 402 individuals who transferred into one of the facilities already on 
ART, was 95% (92%-97%) 6 months post transfer (0 deaths, 18 LTFU) and 94% (90%-96%) 
(0 deaths, 20 LTFU) at 12 months. Over half the individuals LTFU (11/20) did not return after 
their first registration visit.  
   
Discussion 
The last 5 years have seen rapid changes in both PMTCT guidance and practice and CD4 
threshold recommendations for ART initiation. The Lablite project 13 was working with 
Ministries of Health in Malawi, Zimbabwe and Uganda between 2011-2015 and collating 
routine data on ART rollout in non-research facilities in rural areas. In Zimbabwe, this 
provided an important opportunity to compare ART initiations and retention on ART before 
and after introduction of Option B+ and the increase in CD4 threshold.  
 
We found that following Option B+ implementation and the increased CD4 threshold, greater 
numbers of all patients started ART, including children. Patients who started ART at 
CD4>350 or for Option B+ (with high CD4) inevitably did so as a result of guideline changes; 
however increases in other patient groups may have occurred anyway. Devolvement of ART 
care to the primary care staff with support from MOHCW allowed management of increasing 
patient numbers. However drug supply remains a concern; although no stock-outs of ART 
were reported there were anecdotal reports of patients having to return to clinic in between 
scheduled visits to collect ART because of low supplies, and stock-outs of cotrimoxazole did 
occur. 
 
Overall mortality was low and retention in care was extremely good in patients starting ART 
for disease progression (93% at 12 months), better than reported for the ART programme in 
Zimbabwe between 2007-2010 15 and in other settings. 16 Retention was higher at the 
hospital than in the primary care facilities, possibly because of the Lablite model of training 
whereby hub staff received additional training to mentor staff at primary care facilities. 
Encouragingly we found no evidence that introduction of Option B+ had a detrimental effect 
on retention of patients starting ART for disease progression. Retention on ART was poorer 
in Option B+ women than in other adults starting ART, as found in Malawi, 17  but similar to 
retention reported in other rural districts of Zimbabwe (83%).18 At all four Lablite facilities, 
women were asked to start ART immediately; for many HIV is a new diagnosis following 
routine testing during antenatal care and qualitative work suggests immediate treatment may 
be difficult because of the limited time available to digest a positive HIV diagnosis and 
understand and form decisions around the uptake of a new life-long treatment.17,19 
 
CD4 counts were obtained for 85% of men and non-pregnant/breastfeeding women prior to 
ART with no drop in testing after Option B+ implementation or increase in CD4 threshold. 
Numbers of men and non-pregnant/breastfeeding women starting ART with CD4>350 were 
encouraging, suggesting these individuals can be identified, although we could not 
distinguish individuals newly diagnosed from those already in pre-ART HIV care. Despite 
this, a significant proportion still start ART with low CD4s, particularly men, who are more 
likely to present later than women. 20,21 Around half Option B+ women had a pre-ART CD4 
recorded; facilities were asked to continue providing CD4s (unlike in Malawi where CD4s are 
not offered to pregnant/breastfeeding women 13); it is unclear whether remaining women had 
no CD4 measured or whether it was not recorded. Assuming recorded CD4s were 
representative in Option B+ women, importantly >40% pregnant/breastfeeding needed ART 
for their own disease (either WHO stage 3/4 or CD4≤350), consistent with other studies. 22  It 
is important that these women are retained on ART for their own health as well as to prevent 
MTCT; healthcare workers may need focused training to support retention of Option B+ 
women with low CD4 counts.  
 
Among Option B+ women, almost all attrition was recorded as LTFU; unrecorded deaths are 
unlikely to be a major contributor but we cannot distinguish between women who have 
“silently” transferred to other health facilities and those who have dropped out of care 
completely. Age was a clear factor in predicting loss to follow-up, with younger women more 
likely to be lost. This corroborates findings in Malawi 23,24 and Zimbabwe.18 Targeted support 
measures are needed for the increasing numbers of HIV-infected adolescent and young 
pregnant women starting ART. We were only able to look at retention on ART to 12 months 
and it is important to recognise that losses in this period, the majority of which were very 
early, are likely to have been during pregnancy or breastfeeding. In Malawi it is estimated 
that half of those lost in the first 6 months may never have started ART. 8 In Zimbabwe 
patients are asked to return to clinic 2 weeks after starting ART, which is earlier than 
elsewhere (including Malawi). We found that around 2/3 of women who were lost by 1 month 
had returned for their 2-week visit; this raises concerns that they took ART for only a short 
time and may now have developed resistance as the half-life of efavirenz maybe much 
longer than other drugs. Data from Malawi suggest that the risk of loss to follow-up is much 
lower after the first year; 24 however, it will be some time before comparable data are 
available for Zimbabwe. 
 
In Zimbabwe since Option B+ roll-out, policy has been to encourage male partners to attend 
antenatal care with pregnant women and to provide them with ART, irrespective of their own 
CD4 count. However, this seems to have happened very rarely (only 3 men). Initiatives to 
engage men are critical as lack of male involvement and the complex dynamics between the 
women and their partners including concerns about stigma are cited by healthcare workers 
as a common reason for non-retention among women on Option B+. 25,26  
  
Historically HIV-infected children have been seen in secondary and tertiary health care 
facilities in Zimbabwe 27 so it was encouraging to see ART initiations in under 15’s at all 
facilities, including the new primary care facility (where ART provision was introduced 
alongside Option B+). However, similar to other studies, 28 children <24 months were treated 
almost exclusively at the hospital, suggesting possible reluctance to test and treat infants in 
primary care. Retention on ART was also somewhat lower in children than in adults starting 
ART outside of Option B+. Previous studies of retention in care of HIV-exposed and infected 
children have identified a range of possible risk factors including characteristics of the carer 
for mortality and loss to follow-up; 29-31 further research is needed to develop strategies to 
mitigate losses. 
 
Following the START and TEMPRANO trials 32,33, WHO released new guidelines 
recommending that all HIV-infected individuals should start treatment as soon as possible 
after a positive diagnosis.34 It is unclear how quickly this recommendation will be taken up in 
sub-Saharan Africa. Our early data on uptake of treatment in individuals with CD4>350 
following the rise in threshold suggest that there will be demand. If adopted, lessons may be 
learned from Option B+ roll-out; immediate treatment following provider initiated testing in 
“well” patients may not be dissimilar. In particular, adopting treatment for all may facilitate 
retention of pregnant/breastfeeding women by reducing the current disparity in access to 
ART between women and their partners. 
 
Strengths of the Lablite project include the study of rural MOHCW facilities with little/no 
research experience and use of routine data collected from paper records.  This contrasts 
with much of the existing Option B+ operations research which primarily focuses on larger 
health facilities with electronic data capture. Additionally we have data before and after the 
introduction of Option B+ and changes in WHO CD4 threshold guidelines and across all 
patient groups. The primary weaknesses include lack of information on the underlying 
causes of patients LTFU (common to most studies) and use of a retrospective definition of 
LTFU (often used in analysis of routinely-collected data where visit data may be incomplete). 
Our study is limited to four facilities and it remains important to collate further data to 
determine how generaliseable our findings are. 
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Figure Legends 
Figure 1: Number of new ART initiations by patient status at ART initiation, time period and 
health facility (PC=primary care facility) 
Figure 2: Cumulative incidence of death or default (LTFU) by time since ART initiation 
 Table 1 Characteristics at ART initiation in a District Hospital and two primary care facilities 
with established ART provision prior to Option B+ implementation1  
 Pre Option B+ 0-6 months post Option 
B+ 
7-12 months post Option 
B+ 
Total 
 Sep 2013-Feb 2014 Mar 2014-Aug 2014 Sep 2014-Feb 2015  
 Median 
(IQR) 
N % of 
total 
or of 
sub-
group 
Median 
(IQR) 
N % of 
total 
or of 
sub-
group 
Median 
(IQR) 
N % of 
total 
or of 
sub-
group 
N % of 
total 
or of 
sub-
group 
Total2  300   869   463  1632  
            
Children  36 12  60 7  43 9 139 9 
Age 4 (2-9)   5 (2-11)   6 (2-8)     
≤2 years  10 28  16 27  14 33 40 29 
3-14 years  26 72  44 73  29 67 99 71 
            
Adult Males  112 38  227 26  156 34 495 31 
Age 38 
(33,45) 
  37 
(32,43) 
  37 
(32,43) 
    
WHO stage            
 Stage 1/2  19 17  68 30  35 22 122 25 
 Stage 3  90 81  159 70  121 78 370 75 
 Stage 4  2 2  0 0  0 0 2 0.4 
CD43 143 
(71,243) 
  215 
(103,341) 
  216 
(112,321) 
    
  CD4≤100  29 36  46 25  33 23 108 26 
 CD4 101-200  27 34  38 20  31 22 96 23 
 CD4 201-350  22 28  59 32  48 34 129 32 
CD4 351-500  2 3  38 20  28 20 68 17 
CD4>500  0 0  5 3  3 2 8 2 
            
Non-pregnant & 
non-
breastfeeding 
adult females 
 110 38  224 26  180 39 514 32 
Age 35 
(29,42) 
  34 
(30,40) 
  34 
(28,42) 
    
WHO stage            
 Stage 1/2  20 18  66 29  46 26 132 26 
 Stage 3  88 81  157 70  132 73 377 73 
 Stage 4  1 1  1 0.5  2 1 4 1 
Table1
CD44 192 
(89,263) 
  295 
(172,398) 
  266 
(152,395) 
    
 CD4≤100  24 28  20 10  27 16 71 16 
 CD4 101-200  21 24  43 22  41 24 105 23 
 CD4 201-350  38 44  63 33  45 26 146 33 
CD4 351-500  4 5  62 32  54 32 120 27 
CD4>500  0 0  4 2  3 2 7 2 
            
Pregnant or 
breastfeeding 
adult females 
 34 12  351 41  84 18 469 29 
            
Age 28 
(26,31) 
  29 
(24,33) 
  26 
(21,32) 
    
Pregnant  18 53  182 52  57 68 257 55 
WHO stage            
 Stage 1/2  12 36  305 87  71 85 388 83 
 Stage 3  20 61  46 13  13 16 79 17 
 Stage 4  1 3  0 0  0 0 1 0.2 
CD45 250 
(148,307) 
  454 
(304,613) 
  339 
(245,501) 
    
 CD4≤100  5 18  12 7  3 8 20 8 
 CD4 101-200  6 21  16 9  4 11 26 11 
 CD4 201-350  17 61  29 19  12 32 58 24 
CD4 351-500  0 0  44 26  8 22 52 22 
CD4>500  0 0  71 41  10 27 81 34 
 
1Zowa primary care health facility is not included as there was no ART provision prior to Option B+, 
hence its inclusion post Option B+ could distort comparisons 
215 individuals with missing age excluded from sub-groups below 
3CD4 at initiation was available in 80 (71%), 186 (82%), 143 (92%) males by time period  
4CD4 at initiation was available in 87 (79%), 192 (86%), 167 (93%) non-pregnant & non-breastfeeding 
females by time period 
5CD4 at initiation was available in 28 (82%), 172 (49%), 37 (44%) pregnant or breastfeeding females 
by time period 
Table 2: Predictors of death and loss to follow-up from care in adults newly starting ART 
 
 Initiated for WHO stage 3/4 or CD4<threshold Initiated for Option B+ 
 Univariable analysis Multivariable analysis* Univariable analysis Multivariable analysis* 
 N=1,140 (58 failures)1 N=904 (41 failures)2 N=386 (58 failures)3 N=386 (58 failures) 
 HR (95% CI) p HR (96% CI) p HR (95% CI) p HR (95% CI) p 
Site         
Hospital 1.00   1.00  1.00    
Nyabira (PC) 7.52 (3.85-14.7)  7.32 (2.96-18.1)  1.12 (0.60-2.09)    
Mutorashanga (PC) 3.74 (1.90-7.36)  4.02 (1.72-9.41)  0.61 (0.29-1.28)    
Zowa (PC) 1.38 (0.18-10.5) <.001 - <.001 - 0.33   
Initiation period         
Sep 2013-Feb 2014 1.0  1.00  -    
Mar 2014-Feb 2015 0.51 (0.30-0.87) 0.01 0.42 (0.21-0.86) 0.02 -    
Sex         
Male 1.00    -    
Female 0.92 (0.55-1.55) 0.77   -    
Age at initiation (per 
year increase) 
0.97 (0.95-1.00) 0.07   0.94 (0.90-0.98) 0.01 0.94 (0.90-0.98) 0.01 
WHO stage at initiation         
WHO 1/2 1.00  1.00  -    
WHO 3 0.55 (0.32-0.95)  0.56 (0.27-1.18)  -    
WHO 4 4.35 (1.02-18.6) 0.004 4.95 (0.99-24.7) 0.01 -    
CD4 at initiation (per 10 
cell/mm3 increase) 
0.97 (0.95-1.00) 0.024 0.97 (0.95-1.00) 0.03 1.00 (0.98-1.01) 0.67   
Pregnant/breastfeeding         
No/male 1.00  1.00  -    
Either pregnant or 1.98 (0.97-4.04) 0.06 2.68 (0.99-7.25) 0.05 -    
Table2
breastfeeding 
Pregnant -    1.00    
Breastfeeding -    0.83 (0.49-1.41) 0.49   
PC: primary care facility.  
* All variables presented in the univariable analysis were considered for inclusion in the multivariable model. Continuous variables (CD4 and age) were included as fractional 
polynomials for model selection which was based on backwards elimination (P<0.10).  
1Due to missing data, CD4 model (N=944, failures=41); WHO stage model (N=1,137, failures=58); 2Patients with missing CD4 or WHO stage or at Zowa (no Pre Option B+ 
data) were dropped in the final model; 3Due to missing data, CD4 model (N=193, failures=28); due to no failures at Zowa, site model (N=379, failures=58); 4CD4 in the 
univariable model was better represented by CD4-0.5 but we show the linear term here for comparability with the multivariable model and for ease of interpretation. 
 
 
Table 3: Predictors of death and loss to follow-up from care in adults newly starting ART for WHO stage 3/4 or CD4<threshold 
 
 Death and loss to follow-up Loss to follow-up Death 
 N=904 (41 failures)1 N=904 (28 failures)2 N=904 (13 failures)2 
 HR (96% CI) p cHR (95% CI) p cHR (95% CI) p 
Site       
Hospital 1.00  1.00  1.00  
Nyabira (PC) 7.32 (2.96-18.1)  8.56 (3.00-24.4)  4.01 (0.23-70.4)  
Mutorashanga (PC) 4.02 (1.72-9.41)  0.97 (0.25-3.71)  41.7 (4.63-376.1)  
Zowa (PC) - <.001 - <0.001 - 0.001 
Initiation period       
Sep 2013 – Feb 2014 1.00  1.00  1.00  
Mar 2014 – Feb 2015 0.42 (0.21-0.86) 0.02 0.56 (0.23-1.36) 0.20 0.19 (0.04-0.96) 0.04 
WHO stage at initiation       
WHO 1/2 1.00  1.00  1.00  
WHO 3 0.56 (0.27-1.18)  0.71 (0.28-1.79)  0.20 (0.04-1.04)  
WHO 4 4.95 (0.99-24.7) 0.01 7.63 (0.79-74.1) 0.07 1.75 (0.17-17.7) 0.09 
CD4 at initiation (per 10 
cell/mm3 increase) 
0.97 (0.95-1.00) 0.03 0.99 (0.97-1.02) 0.54 0.90 (0.84-0.97) 0.003 
Pregnant/breastfeeding       
No/male 1.00  1.00  -  
Either pregnant or 
breastfeeding 
2.68 (0.99-7.25) 0.05 5.58 (1.82-17.1) 0.07 -3 - 
PC: primary care facility. cHR: cause-specific hazard ratio 
1Model selected in multivariable analysis for combined endpoint (death and loss to follow-up), see table 2. 2The full multivariable model was run for each competing event, 
censoring the alternative event. 3There were no deaths among the pregnant and breastfeeding women. 
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